Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge

被引：29

作者：

Yang, Ying ^{[1
]}

Yu, Yongfeng ^{[1
]}

Lu, Shun ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai 20030, Peoples R China

来源：

SCIENCE CHINA-LIFE SCIENCES | 2020年 / 63卷 / 10期

基金：

中国国家自然科学基金;

关键词：

immunotherapy; PD-1; PD-L1; inhibitors; lung cancer; OPEN-LABEL; CHECKPOINT INHIBITORS; CO-STIMULATION; PD-L1; BLOCKADE; EXPRESSION; NIVOLUMAB; DOCETAXEL; RESISTANCE; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.1007/s11427-019-1622-5

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Immune checkpoint inhibitors (ICIs), especially inhibitors of the PD-1/PD-L1 axis, have significantly affected the outcomes of patients with lung cancer. Nivolumab and pembrolizumab have been approved as PD-1 blocking antibodies, whereas atezolizumab, avelumab, and durvalumab are approved as PD-L1 blocking antibodies by the United States Food and Drug Administration. However, which patient may benefit the most and how to identify patients at risk of primary or acquired resistance has not been completely defined. Meanwhile, close attention has been paid to the ongoing international and domestic clinical trials in Chinese patients with lung cancer. This review aimed to provide deep insight into the effectiveness of PD-1/PD-L1 inhibitors in patients with lung cancer, including the current settings for varied disease status, the predictive biomarkers, the resistance to ICIs, and the ongoing clinical trials in Chinese patients.

引用

页码：1499 / 1514

页数：16

共 77 条

[1] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].

Agata, Y ;

Kawasaki, A ;

Nishimura, H ;

Ishida, Y ;

Tsubata, T ;

Yagita, H ;

Honjo, T .

INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772

[2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[3] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[4] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[5] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[7] Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% [J].

Brahmer, J. ;

Rodriguez-Abreu, D. ;

Robinson, A. ;

Hui, R. ;

Csoszi, T. ;

Fulop, A. ;

Gottfried, M. ;

Peled, N. ;

Tafreshi, A. ;

Cuffe, S. ;

O'Brien, M. ;

Rao, S. ;

Hotta, K. ;

Riccio, A. ;

Yang, J. ;

Pietanza, M. C. ;

Reck, M. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1793-S1794

[8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[10] MYC regulates the antitumor immune response through CD47 and PD-L1 [J].

Casey, Stephanie C. ;

Tong, Ling ;

Li, Yulin ;

Do, Rachel ;

Walz, Susanne ;

Fitzgerald, Kelly N. ;

Gouw, Arvin M. ;

Baylot, Virginie ;

Guetgemann, Ines ;

Eilers, Martin ;

Felsher, Dean W. .

SCIENCE, 2016, 352 (6282) :227-231

← 1 2 3 4 5 6 7 8 →